Personalized Comments on Challenges and Opportunities in Kidney Disease Therapeutics: The Glom-NExT Symposium.
Semin Nephrol
; 36(6): 448, 2016 11.
Article
em En
| MEDLINE
| ID: mdl-27987543
In the face of ever-increasing incidence and prevalence of kidney disease worldwide, the unmet need for new treatments is unprecedented. Precision medicine is defined as the use of modern technologies to identify mechanisms of diseases in individual patients, and thus deploy treatment using tailored, targeted approaches, in the hopes of avoiding unnecessary toxicities and complications. Is there a place for kidney disease therapeutics in this space? If so, what is required to make significant progress toward precision nephrology? To answer these critical questions, we present a series of personalized comments corresponding to the responses offered to these very questions during the Inaugural Glom-NExT Symposium held at Harvard Medical School on October 23, 2014, a national meeting focused exclusively on kidney disease therapeutics.
Palavras-chave
ADCK4; APOL1; ARHGDIA; Adaptive trials; B7-1; CD80; COQ6; FSGS; INF2; Rac1; TRPC5; TRPC6; actinin-4; autosomal dominant; clinical trials; consortium; cytoskeleton; integrin; kidney disease; nephrotic syndrome; patient-reported outcomes; podocyte; precision medicine; proteinuria; rare disease; recessive mutations; synaptopodin; targeted therapy
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Medicina de Precisão
/
Nefropatias
Idioma:
En
Ano de publicação:
2016
Tipo de documento:
Article